ETA
If you are planning a family holiday, look no further than Egypt. The country is renowned for its all-inclusive hotels and resorts that cater to the needs of families with children. These resorts offer entertainment programs and excursions suitable for all age groups. Museums and cultural sights also offer family-friendly activities. Furthermore, Egypt's warm temperatures and dry climate throughout the year make it an ideal destination for holidays all year round, with sandy beaches and shallow water that are sure to excite children.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005234/en/
Family Holiday in Egypt (Photo: Business Wire)
What Makes a Holiday Family-Friendly?
A holiday is meant to be a time for relaxation, escaping everyday life and enjoying oneself. However, this can be challenging when traveling with children. Egypt's all-inclusive hotels and resorts provide stress-free options for families with children. The resorts offer animation programs for children of different ages, with pools featuring water slides and children's pools. In addition, multilingual caretakers are available to look after children when parents want to pursue their own plans undisturbed for an afternoon or evening. This allows parents to relax and enjoy their holiday with peace of mind.
Activities for the whole Family
There are many activities that families can enjoy together in Egypt. Clubs and resorts offer a range of sports activities, including mini golf, beach football, and volleyball. For those interested in water activities like diving, snorkelling, or kite surfing, there are beginner courses as well as special children's courses available.
In the cities itself, families can find a variety of activities like water parks, amusement parks, safari tours, and aquariums. Additionally, museums can be a great way to make history exciting for children, with the Egyptian Museum in Cairo offering guided tours specifically designed for kids. Outside of the cities, families can have adventures like desert tours in buggies or riding on camels. Compared to similar activities in Europe, leisure activities in Egypt are much more affordable, allowing families to experience more together or take some time for themselves to relax.
"Nile Trips and Abu Simbel"
Aswan, the southernmost city in Egypt, is located directly on the Nile, making it an excellent starting point for interesting and varied tours. Visitors can take Nile trips to the temples of Kom Ombo and even further north to Luxor. Close to the city lies Lake Nasser, at the southern end of which stands the spectacular temple complex of Abu Simbel. The four 20-metre-high statues of Pharaoh Ramses II at the main entrance of the temple are an incomparable sight and rightly rank among the most popular sights in the country.
Aswan itself is also full of treasures to discover, such as the Agha Khan Mausoleum on the west bank of the Nile, or the archaeological Nubian Museum that highlights the history of the Nubian population, who make up a large part of Aswan's inhabitants. The city also includes numerous islands in the Nile, such as Elephantine Island, or Kitchener Island to the north, where the city's botanical garden can be found.
Background information on the Egyptian Tourism Authority
The Egyptian Tourism Authority (ETA) was established in 1981 to boost international tourism by highlighting Egypt's long history and traditional civilization and promoting the country and its many tourist attractions. ETA's mission also includes promoting domestic tourism, raising awareness of tourism throughout the country, and strengthening the connection between Egyptians and their heritage.
The ETA's focus is on the one hand on the diversity of attractions and destinations within Egypt, and on the other hand on developing marketing strategies and programs to promote tourism, as well as providing technical and marketing support. It also organizes and sponsors tourism, sports, and social and cultural events throughout the country. The ETA Board of Directors is chaired by the Minister of Tourism.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005234/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
